AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03159351 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment
Description: sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
Study NCT03636373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
Study NCT03636373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
Study NCT01010087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
Study NCT01010087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
Study NCT01280604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 54mg
Description: Subjects will receive fenofibrate 54mg daily.
Study NCT02119338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ala
Description: dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
Study NCT04429802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Orally administered
Study NCT04429802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered
Study NCT04213677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.
Study NCT04213677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.
Study NCT00085397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-tumor fusion vaccine
Description: Given subcutaneously
Study NCT00085397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given IV
Study NCT00085397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given IV
Study NCT01472614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Description: Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
Study NCT03387813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS™ HF System
Description: The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
Study NCT00459797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (reusable) Glidescope
Study NCT00459797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-use Glidescope videolaryngoscope
Study NCT03625453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration
Study NCT03625453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: 8 weeks with daily administration
Study NCT04160806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
Study NCT04160806 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
Study NCT00358644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
Study NCT04276298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole cream
Description: 10% metronidazole applied rectally
Study NCT04276298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole and Diltiazem cream
Description: Combination Metronidazole and Diltiazem applied rectally
Study NCT04276298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole and Lidocaine cream
Description: Combination metronidazole and lignocaine applied rectally
Study NCT04276298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole, Diltiazem and Lidocaine cream
Description: Combination of all active agents tested applied rectally
Study NCT02628483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 1000mg fish oil per capsule (325mg EPA + 225mg DHA)
Study NCT02628483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: 1000mg fish oil per capsule (300mg EPA + 200mg DHA)
Study NCT04380883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnoSEAL+TRB
Description: InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
Study NCT04380883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRB alone
Description: TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
Study NCT03289702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORETOX®
Description: Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
Study NCT03289702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
Study NCT01405677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epaxal 0.25 mL
Description: 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
Study NCT01405677 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epaxal 0.5 mL
Description: 24 IU hepatitis A antigen coupled to IRIV
Study NCT01405677 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix Junior 0.5 mL
Description: 720 EU hepatitis A antigen absorbed onto aluminum hydroxide
Study NCT03989921 — intervention group
Intervention type: OTHER
Intervention: no intervention. observational study
Description: no intervention. observational study
Study NCT00535093 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: rapid streptococcal testing
Description: Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
Study NCT03310398 — intervention group
Intervention type: BEHAVIORAL
Intervention: NeuroImaging
Description: standard anatomical and functional imaging
Study NCT03310398 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychophysiological
Description: Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
Study NCT00746356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing of the autocapture features of the device
Description: Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
Study NCT00746356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing of the autocapture features of the device
Description: Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
Study NCT04115267 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Combined modality
Study NCT04833244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Triangular Forearm Support
Description: The intervention, the Triangular Forearm Support requires drawing the shoulders away from the subject's head and neck. This requires at least a mild force that this action can oppose. The most-favored maneuver is to have patients stand 2 feet away from a wall, interlock their fingers, and place their forearms to form two sides of an equilateral triangle against the wall. They then place their heads within the triangle, the backs of their heads close to or in on contact with the heels of their hands. Then, pressing against the wall with their elbows and forearms, they draw their shoulders as far away from the wall as possible, retaining contact between the wall and the tops of their heads. Subjects remain in this position for 45 seconds, at which time they stand erect and repeat the abduction and flexion maneuver.
Study NCT04833244 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be asked to raise arms overhead for 45 seconds.
Study NCT05111743 — intervention group
Intervention type: DRUG
Intervention: Brolucizumab
Description: Participants received brolucizumab injection during the index period
Study NCT03096756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GC4702 dry powder
Description: 5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
Study NCT03096756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GC4702 lipid suspension
Description: 112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
Study NCT03096756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GC4419 IV
Description: infused IV as a single dose of 27 mg (3 mL GC4419 at 9 mg/mL) in 247 mL normal (0.9%) saline, totaling 250 mL, over a 60minute period using a programmable pump.
Study NCT03096756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Dry Powder
Description: Product matches appearance of the GC4702 dry powder formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
Study NCT03096756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo lipid suspension
Description: Product matches appearance of the GC4702 lipid suspension formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
Study NCT03096756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines7 consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively.
Study NCT03096756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Condition
Description: For the fasting condition, GC4702 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
Study NCT03096756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4702 lipid suspension - Part 2
Description: Two single doses of GC4702 (dose level to be selected based on Part 1 results), separated by a 7-day washout period
Study NCT02240797 — intervention group
Intervention type: OTHER
Intervention: Positron emission tomography (PET) imaging
Description: Positron emission tomography (PET) imaging
Study NCT00827736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
Study NCT00827736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
Study NCT00827736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISDN ointment
Description: application of ISDN 1% ointment 6 times a day
Study NCT00827736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)
Study NCT04344665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Care and Remote Automated Monitoring
Description: Patients will measure daily vitals (blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, weight) with remote monitoring technology and complete recovery surveys daily in home after discharge from hospital. Patients will interact with a virtual nurse daily on days 1-15 and every other day from days 16-30. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician. Physicians will add or modify treatments as needed, and if required, they will have the patient come to an outpatient facility for evaluation or management. Via secure video or text messaging, patients will also have access to a virtual nurse at night, for any urgent issues.
Study NCT03021278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline injection
Description: In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
Study NCT03021278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
Study NCT04629937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPECT acquisitions
Description: All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
Study NCT01463228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Study NCT01463228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study NCT01982175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3\~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~--------------------------------------------------------------------------------
Study NCT01240252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human insulin
Description: U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
Study NCT01240252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
Study NCT01475422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Maps Diabetes Education
Description: The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
Study NCT01475422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
Study NCT03954288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum for sclerostin ELISA test
Description: Blood sample to measure serum sclerostin level
Study NCT01545557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid dermal filler gel
Description: 1 Emervel Volume injection per indication and 1 touch-up injection if necessary
Study NCT04488042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stapler-less gastrectomy
Description: After the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
Study NCT04488042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: No reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
Study NCT03214549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gull wing preparation of laminates veneers
Description: preparation involving mesial and distal extension further lingualy.
Study NCT03214549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional preparation of laminates veneers
Description: preparation not involving mesial and distal extension further lingualy.